Researchers at Oregon Health & Science University reported that AAV gene therapy expressing a CCR5-blocking antibody can drive long-term viral suppression in SHIV-infected macaques. The approach uses AAV delivery of a leronlimab-derived antibody designed to interrupt viral entry by targeting the CCR5 co-receptor. In treated macaques, most produced detectable antibody levels after AAV administration, with about half mounting an immune response that generated antidrug antibodies. Even with immune responses, the study observed stable expression in some animals, while those without immune responses maintained expression over the full observation period. The work supports continued interest in long-acting gene-based antibody delivery for HIV cure research, where sustained suppression can reduce reliance on daily antiretroviral therapy and may address adherence limitations.